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Abstract
Background: Recent findings suggest that αE expression is enriched on effector T cells and that 
intestinal αE+ T cells have increased expression of inflammatory cytokines. αE integrin expression 
is a potential predictive biomarker for response to etrolizumab, a monoclonal antibody against β7 
integrin that targets both α4β7 and αEβ7. We evaluated the prevalence and localization of αE+ cells 
as well as total αE gene expression in healthy and inflammatory bowel disease patients.
Methods: αE+ cells were identified in ileal and colonic biopsies by immunohistochemistry and 
counted using an automated algorithm. Gene expression was assessed by quantitative reverse-
transcriptase polymerase chain reaction.
Results: In both healthy and inflammatory bowel disease patients, significantly more αE+ cells 
were present in the epithelium and lamina propria of ileal compared with colonic biopsies. αE gene 
expression levels were also significantly higher in ileal compared with colonic biopsies. Paired 
biopsies from the same patient showed moderate correlation of αE expression between the ileum 
and colon. Inflammation did not affect αE expression, and neither endoscopy nor histology scores 
correlated with αE gene expression. αE expression was not different between patients based on 
concomitant medication use except 5-aminosalicylic acid.
Conclusion: αE+ cells, which have been shown to have inflammatory potential, are increased in 
the ileum in comparison with the colon in both Crohn’s disease and ulcerative colitis, as well as 
in healthy subjects. In inflammatory bowel disease patients, αE levels are stable, regardless of 
inflammatory status or most concomitant medications, which could support its use as a biomarker 
for etrolizumab.
Key Words:  Integrin alphaE; CD103; inflammatory bowel disease; ulcerative colitis; Crohn’s disease.
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1. Introduction
Inflammatory bowel disease [IBD] is characterized by intestinal 
inflammation that results from an abnormal immune response to 
the gut microbiome.1 IBD encompasses both Crohn’s disease [CD], 
characterized by transmural and patchy disease distribution that can 
occur anywhere along the gastrointestinal tract and most commonly 
affects the ileum or ileum and proximal colon, and ulcerative colitis 
[UC], which presents as continuous mucosal inflammation restricted 
to the colon and rectum. IBD pathobiology is probably driven by 
complex interactions between host genetics, immune dysregulation, 
the gastrointestinal microbiota and environmental factors that are 
incompletely understood.2
Interactions between integrins and adhesion molecules mediate 
homing of leukocytes to peripheral tissues.3 The binding of α4β7 
integrin to mucosal vascular addressin cell adhesion molecule 1 
[MAdCAM-1], an adhesion molecule expressed on high endothelial 
venules in the lamina propria [LP] and Peyer’s patches, is involved in 
gut-specific leukocyte trafficking. Clinical studies have demonstrated 
the importance of this pathway, as blocking antibodies against β7 
integrin,4 the α4β7 integrin5–7 heterodimer or MAdCAM-18 have 
all demonstrated clinical efficacy in UC. Etrolizumab is a human-
ized monoclonal anti-β7 antibody with a dual mechanism of action, 
inhibiting both α4β7:MAdCAM-1–mediated lymphocyte trafficking 
to the gut mucosa as well as αEβ7:E-cadherin–mediated lympho-
cyte retention in epithelium. The αE integrin subunit [also known 
as CD103] exclusively pairs with the β7 integrin subunit to form an 
αEβ7 integrin heterodimer, which is expressed on a subset of intes-
tinal T cells as well as dendritic cells [DCs], mast cells9 and innate 
lymphocytes.10 Because αE pairs only with β7, detection of αE alone 
by gene or protein expression implies rather than directly demon-
strates that αEβ7 is expressed by a cell; hence, αE+ cells are referred 
to as such throughout. αE+ cells are retained in the gut epithelium 
through binding of αEβ7 integrin on their cell surface to E-cadherin 
expressed on epithelial cells. Blockade of both α4β7 and αEβ7 
resulted in decreased accumulation of adoptively transferred T cells 
in the intestinal mucosa in comparison with blockade of α4β7 alone 
in a humanized mouse model.11 In a phase 2 study of etrolizumab 
in UC patients, crypt-associated αE+ cells were decreased follow-
ing etrolizumab treatment. In a post hoc analysis in the same study, 
higher rates of remission were observed in etrolizumab-treated UC 
patients with above-median levels of αE in baseline colonic biopsies.4
Initial work in mouse models associated αE expression with 
regulatory T cell function.12,13 In humans, emerging data support an 
inflammatory rather than a regulatory role for αE+ T cells. Th9 and 
Th17 effector T cells in the peripheral blood have increased expres-
sion of αE in comparison with regulatory T cells.11 FOXP3+ cells 
in the gut mucosa rarely have co-expression of αE,11,14 and sorted 
intestinal αE+ T cells have low gene expression of FOXP3 and asso-
ciated regulatory co-stimulatory molecules and cytokines.14 Instead, 
intestinal αE-expressing T cells have higher levels of pro-inflam-
matory cytokines and effector molecules compared with T cells 
lacking expression of αE.14,15 In addition, studies have shown that 
αE-expressing T cells can target and kill epithelial cells in vitro and 
may mediate localized tissue damage.16 Early studies suggest a higher 
prevalence of αE+ cells in the ileum and proximal colon,17–20 indicat-
ing that αE+ cells may be of particular interest for CD pathobiology.
We undertook studies to evaluate αE+ cells in UC, CD and 
healthy subjects, both to characterize the prevalence and localization 
in the intestine as well as to test the association of these cells with 
active inflammation. Our findings on the distribution and stability 
of these measurements in IBD are relevant given the potential for 
biopsy-based predictive biomarkers for etrolizumab.
2. Methods
2.1. Patients
Three cohorts of patients were included in this study. In the first 
cohort, immunohistochemistry [IHC] was used to perform a retro-
spective analysis on formalin-fixed biopsy samples taken from 
IBD and healthy control patients undergoing endoscopic assess-
ment as part of standard clinical care in Newcastle upon Tyne, UK 
[CD patients, n = 48; UC patients, n = 72; healthy control subjects, 
n = 91]. In this cohort [IHC cohort], active disease in the ileum or 
colon was defined as visible mucosal inflammation endoscopically 
and histological confirmation of active inflammation via examin-
ation by a pathologist. Inactive disease in the ileum or colon was 
defined as lack of visible inflammation at endoscopy and histological 
inflammation by pathologist examination.
A second cohort [qPCR cohort] comprised IBD patients and 
healthy control subjects enrolled into a prospective single-time point 
observational study21 designated as EMBARK. All patients under-
went a full ileo-colonoscopy, and biopsies were taken in both the 
ileum and the colon. A subset of patients had mucosal biopsy-derived 
RNA available for analysis [CD patients, n = 63; UC patients, n = 30; 
healthy subjects, n = 14].22 Active disease in EMBARK was defined 
as a Mayo Clinic endoscopic subscore [MCSe] ≥ 2 for UC patients 
and as a Simple Endoscopic Score for Crohn’s Disease [SES-CD]23 
≥ 7, or ≥ 4 for ileum-only CD patients.24 Patients with endoscopic 
evidence of inflammation whose biopsies lacked active histological 
inflammation were excluded from the analysis.
Biopsy variability was evaluated in a third cohort consisting of 
UC patients [n  = 6] and healthy subjects [n  = 5] enrolled into an 
observational study with no therapeutic intervention. Four biopsies 
were collected from each subject at 2-cm intervals along the sigmoid 
colon. Disease activity was evaluated by MCS endoscopic subscore 
and histological assessment.
Written informed consent was obtained in accordance with 
research and ethics committee [REC] [Newcastle and North 
Tyneside 1 REC 10/H0906/41 & Newcastle and North Tyneside 2 
REC 22/02] and institutional review boards’ [IRB] approval at each 
study site. These studies were performed according to the principles 
of the Declaration of Helsinki.
2.2. Immunohistochemistry
Biopsies were fixed in formalin and processed for immunohistochem-
istry as previously described.4 Briefly, 4-μm sections were stained 
using a Benchmark XT [Ventana Medical Systems] autostainer with 
anti-integrin αE antibody [EPR4166; Abcam]. Images were acquired 
using the Olympus Nanozoomer automated slide scanning platform 
[Hamamatsu Photonics] and analysed in the MATLAB software 
package [version R2012a; The MathWorks] to generate total αE+ 
cell counts. Individual cells were identified using an algorithm based 
on radial symmetry,25 and cells were scored as positive or negative 
for 3,3′-diaminobenzidine [DAB] staining using a blue-normalized 
algorithm to identify brown pixels.26 Epithelium was identified as 
previously described4,14 and αE+ cells within one cell diameter of the 
epithelium were identified and counted. LP areas were identified 
using a specific combination of morphology, cell density and manual 
annotation that included only LP and excluded crypts, surface epi-
thelium and lymphoid aggregates.
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2.3. Gene expression analysis
Biopsies were collected and processed as previously described.22 
Briefly, intestinal biopsies were collected from uninflamed or 
inflamed areas [if present] as judged by the endoscopist. RNA was 
isolated using the RNeasy kit [Qiagen], and samples with high 
RNA quality [RNA integrity number ≥ 5] were included in the ana-
lysis [n = 229]. Quantitative PCR [qPCR] was performed using the 
BioMark HD System [Fluidigm] using primer sets specific for CD3ε, 
ITGAE [αE] or TMEM55B [Applied Biosystems]. Technical repli-
cates with a standard deviation ≥ 2 or a standard deviation ≥ 1 with 
an average Ct < 25 were removed from the analysis. Gene expression 
was normalized to TMEM55B using the ΔCt method. Paired ana-
lysis of ileal and colonic biopsies only included uninflamed biopsies 
from the same patient. Paired analysis of uninflamed–inflamed biop-
sies was performed on biopsies from the same anatomical region 
within each patient.
2.4. Statistical analysis
Statistical analysis was performed using Prism5 [GraphPad soft-
ware] and JMP11 [SAS]. Patient demographics were assessed using 
the chi-squared test. Statistical significance between independent 
groups was assessed using the Mann–Whitney test. Paired analysis 
was performed using the Wilcoxon matched-pairs signed-rank test. 
Correlation was assessed by Spearman’s rho. Mean and standard 
deviation are shown on all plots. For concordance analysis, αE 
status was defined as being above the median in both organs or 
below the median in both organs. For variability analysis, the stand-
ard deviation was calculated for the biopsies from a single patient 
[intrapatient] and for the biopsies from all patients at a particular 
collection distance [interpatient]. A  binomial test was performed 
to assess the differences between intrapatient and interpatient vari-
ability. Statistical significance [P < 0.05] was defined based on nom-
inal p values, and different levels were noted on graphs as follows: 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
3. Results
Patient demographics between cohorts were generally similar, with 
some key differences in disease activity and duration as well as cur-
rent therapies [Table  1]. There were more active CD patients in 
the IHC cohort than in the qPCR cohort [active CD: IHC cohort, 
63%, vs qPCR cohort, 22%; P < 0.0001]. UC patients in the IHC 
cohort were older than in the qPCR cohort [median age: IHC cohort, 
54 years, vs qPCR cohort, 41 years; P < 0.01]. A longer disease dur-
ation was reported in the CD qPCR cohort in comparison with the 
IHC cohort [qPCR cohort, median disease duration of 10  years, 
vs IHC cohort, median disease duration of 3  years; P  <  0.05]. 
Therapeutic use was variable across the UC cohorts, with cortico-
steroid use more common in the UC qPCR cohort in comparison 
with the IHC and biopsy variability cohorts [qPCR cohort, 50%, 
vs IHC cohort, 24%, vs biopsy variability cohort, 33%; P < 0.05], 
while anti-tumour necrosis factor [anti-TNF] use was more fre-
quent in the UC biopsy variability cohort in comparison with the 
qPCR cohort [qPCR cohort, 7%, vs biopsy variability cohort, 50%; 
P < 0.0001]. Finally, more UC patients were on 5-aminosalicylic acid 
[5-ASA] therapy in the IHC cohort in comparison with the other 
two cohorts [IHC cohort, 67%; qPCR cohort, 7%; biopsy variabil-
ity cohort, 50%; P < 0.0001].
Biopsies from both the terminal ileum and the colon con-
tained readily detectable αE+ cells in both the LP and the epithe-
lium [Figure  1a]. For this analysis, an average of αE+ cells across 
the region was generated for patients with multiple biopsies. 
Quantification of total αE+ cells by IHC showed that the proportion 
of αE+ cells was significantly higher in the ileum in comparison with 
the colon of patients with UC [ileum, 1334 ± 726.7 cells/mm2, vs 
colon, 575.0 ± 292.6 cells/mm2; P < 0.001] and CD [ileum, 891.6 ± 
442.1 cells/mm2, vs colon, 357.9  ±  153.0 cells/mm2; P  <  0.0001] 
as well as control subjects [ileum, 1107.0  ±  518.7 cells/mm2, vs 
colon, 478.4 ± 279.5 cells/mm2; P < 0.0001] [Figure 1b]. The ileum 
had similar numbers of αE+ cells in IBD patients and healthy sub-
jects. In contrast, there were significant differences in cell density 
between patient groups and healthy controls in the colon. Of the 
three cohorts, CD patients had reduced numbers of αE+ cells in the 
colon [CD 357.9 ± 153 cells/mm2] in comparison with healthy con-
trols [478.4 ± 279.5 cells/mm2, P < 0.05] and UC patients [575 ± 
292.6 cells/mm2, P < 0.0001]. The increased density of αE+ cells in 
colons of patients with UC was also significantly higher than in those 
of healthy subjects [P < 0.05] [Figure 1b].
E-cadherin, the ligand for αEβ7, is expressed on epithelial cells 
in the gut and probably functions to retain αE+ cells at the muco-
sal barrier. The density of αE+ cells in the epithelium was consist-
ently higher in the ileum compared with the colon in patients with 
CD [ileum, 2678  ±  1601 cells/mm2, vs colon, 1392  ±  652 cells/
mm2; P  <  0.01], those with UC [ileum, 4097  ±  2767 cells/mm2, 
vs colon, 2217  ±  1024 cells/mm2; P  <  0.01] and healthy controls 
[ileum, 3910 ± 2003 cells/mm2, vs colon, 1869 ± 1062 cells/mm2; 
P  <  0.0001] [Figure  1c]. Although the majority of αE+ cells were 
localized in the epithelium,9,14 αE+ cells were also observed to local-
ize to the LP with similar trends to intra-epithelial αE+ cells. LP αE+ 
cells were increased in the ileum compared with the colon in CD 
patients [ileum, 861  ±  430.5 cells/mm2, vs colon, 342.6  ±  148.2 
cells/mm2; P < 0.0001], UC patients [ileum, 1300 ± 717.6 cells/mm2, 
vs colon, 551.6  ±  286.6; P  <  0.001] and healthy subjects [ileum, 
1060 ± 498 cells/mm2, vs colon, 459 ± 270.2 cells/mm2; P < 0.0001] 
[Supplementary Figure 1].
Gene expression analysis in biopsies supported the IHC-based 
findings of increased αE+ cells in the ileum compared with the colon. 
For this analysis, a single biopsy was used for each anatomical region 
per patient; uninflamed biopsies, when available, were used to repre-
sent each patient. A two- to four-fold increase in ITGAE [αE] gene 
expression was observed in ileal biopsies in comparison with colonic 
biopsies across both IBD [CD ileum, −1.18  ±  0.90, vs CD colon, 
−2.50  ±  1.11; P  <  0.0001; UC ileum, −1.38  ±  0.44, vs UC colon, 
−2.84 ± 0.92; P < 0.0001] and control samples [ileum, −1.08 ± 1.06, 
vs colon, −2.71 ± 0.85; P < 0.001] [Figure 2a]. An overall increase in 
CD3ε gene expression in ileal biopsies compared with colonic biopsies 
was also observed in patients with CD [ileum, 0.001 ± 0.99, vs colon, 
−1.19 ± 1.12; P < 0.0001] and control samples [ileum, 0.71 ± 0.58, vs 
colon, −0.97 ± 0.90; P < 0.001] [Figure 2b]. No significant differences 
in αE and CD3ε gene expression were observed in intrapatient paired 
uninflamed–inflamed ileal or colonic biopsies [Figure 2c and d].
The proportion of αE+ cells in the ileum and colon were cor-
related in paired patient biopsies, with both total αE+ cells and 
epithelial αE+ cells demonstrating a correlation between the two 
anatomical regions [ρ = 0.48, P < 0.0001; and ρ = 0.39, P < 0.01, 
respectively] [Figure 3a and b]. A significant correlation of αE nor-
malized to CD3ε gene expression levels was observed in patient-
paired ileal and colonic biopsies [ρ = 0.36, P < 0.01] [Figure 3c]. αE 
gene expression alone was not correlated [data not shown]. Biopsies 
used for this analysis were almost exclusively paired uninflamed 
samples, as paired inflamed ileal–colonic biopsies were not available 
in the majority of patients.
AlphaE Integrin Expression in IBD 1193
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/article-abstract/12/10/1191/5038446 by guest on 28 N
ovem
ber 2018
Ta
b
le
 1
. 
Pa
ti
en
t 
d
em
o
g
ra
p
h
ic
s
N
um
be
r 
of
 m
al
es
, 
n 
[%
]
A
ge
, m
ed
ia
n 
[r
an
ge
], 
ye
ar
s
D
is
ea
se
 d
ur
-
at
io
n,
 m
e-
di
an
 [
ra
ng
e]
, 
ye
ar
s
Sm
ok
in
g,
 n
  
[c
ur
re
nt
/f
or
m
er
/n
ev
er
/u
nk
no
w
n]
Im
m
un
o-
 
m
od
ul
at
or
s,
 
n 
[%
]
A
nt
i-
T
N
F,
 n
 [
%
]
C
or
ti
co
st
er
oi
ds
, 
n 
[%
]
5-
A
SA
, n
 [
%
]
IH
C
 C
oh
or
t
H
ea
lt
hy
 [
n 
= 
91
]
40
 [
44
.0
%
]
45
 [
20
–7
8]
-
N
A
-
-
-
-
C
D
 [
n 
= 
48
]*
**
*
18
 [
37
.5
%
]
41
.5
 [
18
–8
2]
3 
[0
–4
3]
*
16
/1
0/
20
/2
14
 [
29
.2
%
]
5 
[1
0.
4%
]
10
 [
20
.8
%
]
8 
[1
6.
7%
]
ac
ti
ve
 [
n 
= 
30
]
14
 [
46
.7
%
]
41
.5
 [
18
–7
5]
2 
[0
–3
6]
9/
7/
13
/1
9 
[3
0.
0%
]
4 
[1
3.
3%
]
8 
[2
6.
7%
]
5 
[1
6.
7%
]
in
ac
ti
ve
 [
n 
= 
18
]
4 
[2
2.
2%
]
41
 [
23
–8
2]
9 
[0
–4
3]
7/
3/
7/
1
5 
[2
7.
8%
]
1 
[5
.6
%
]
2 
[1
1.
1%
]
3 
[1
6.
7%
]
U
C
 [
n 
= 
72
]
42
 [
58
.3
%
]
54
 [
21
–8
3]
**
6.
5 
[0
–5
3]
4/
26
/3
2/
10
12
 [
16
.7
%
]
0 
[0
.0
%
]
17
 [
23
.6
%
]
48
 [
66
.7
%
]*
**
*
ac
ti
ve
 [
n 
= 
35
]
23
 [
65
.7
%
]
51
 [
21
–8
3]
1 
[0
–5
3]
1/
13
/1
8/
3
7 
[2
0.
0%
]
0 
[0
.0
%
]
9 
[2
5.
7%
]
16
 [
45
.7
%
]
in
ac
ti
ve
 [
n 
= 
37
]
19
 [
51
.4
%
]
54
 [
29
–8
0]
14
 [
0–
46
]
3/
13
/1
4/
7
5 
[1
3.
5%
]
0 
[0
.0
%
]
8 
[2
1.
6%
]
32
 [
86
.5
%
]
qP
C
R
 C
oh
or
t1
9
H
ea
lt
hy
 [
n 
= 
14
]
4 
[2
8.
6%
]
53
 [
26
–6
1]
-
2/
5/
7/
0
-
-
-
-
C
D
 [
n 
= 
63
]
31
 [
49
.2
%
]
35
 [
18
–6
5]
10
 [
0–
45
]
17
/1
5/
31
/0
21
 [
33
.3
%
]
4 
[6
.3
%
]
20
 [
31
.7
%
]
20
 [
31
.7
%
]
ac
ti
ve
 [
n 
= 
14
]
7 
[5
0.
0%
]
35
 [
19
–5
9]
6.
5 
[2
–4
5]
5/
4/
5/
0
2 
[1
4.
3%
]
0 
[0
.0
%
]
4 
[2
8.
6%
]
7 
[5
0.
0%
]
in
ac
ti
ve
 [
n 
= 
49
]
24
 [
49
.0
%
]
37
 [
18
–6
5]
10
 [
0–
33
]
12
/1
1/
26
/0
19
 [
38
.8
%
]
4 
[8
.2
%
]
16
 [
32
.7
%
]
13
 [
26
.5
%
]
U
C
 [
n 
= 
30
]
14
 [
46
.7
%
]
40
.5
 [
22
–6
4]
7.
5 
[1
–3
9]
5/
9/
16
/0
7 
[2
3.
3%
]
2 
[6
.7
%
]
15
 [
50
.0
%
]*
2 
[6
.7
%
]
ac
ti
ve
 [
n 
= 
13
]
6 
[4
6.
2%
]
38
 [
24
–6
2]
7 
[1
–1
9]
2/
4/
7/
0
3 
[2
3.
1%
]
1 
[7
.7
%
]
7 
[5
3.
8%
]
1 
[7
.7
%
]
in
ac
ti
ve
 [
n 
= 
17
]
8 
[4
7.
1%
]
48
 [
22
–6
4]
8 
[1
–3
9]
3/
5/
9/
0
4 
[2
3.
5%
]
1 
[5
.9
%
]
8 
[4
7.
1%
]
1 
[5
.9
%
]
B
io
ps
y 
V
ar
ia
bi
lit
y 
C
oh
or
t
H
ea
lt
hy
 [
n 
= 
5]
3 
[6
0%
]
34
 [
26
–4
6]
-
0/
2/
3/
0
-
-
-
-
U
C
 [
n 
= 
6]
4 
[6
6.
7%
]
35
.5
 [
25
–6
2]
5.
5 
[0
–1
0]
1/
2/
3/
0
2 
[3
3.
3%
]
3 
[5
0.
0%
]*
**
*
2 
[3
3.
3%
]
3 
[5
0.
0%
]
ac
ti
ve
 [
n 
= 
3]
3 
[1
00
%
]
38
 [
28
–6
2]
3 
[3
–9
]
0/
2/
1/
0
1 
[3
3.
3%
]
2 
[6
6.
7%
]
2 
[6
6.
7%
]
1 
[3
3.
3%
]
in
ac
ti
ve
 [
n 
= 
3]
1 
[3
3.
3%
]
33
 [
25
–5
0]
8 
[0
–1
0]
1/
0/
2/
0
1 
[3
3.
3%
]
1 
[3
3.
3%
]
0 
[0
.0
%
]
2 
[6
6.
7%
]
5-
A
SA
, 5
-a
m
in
os
al
ic
yl
ic
 a
ci
d;
 C
D
, C
ro
hn
’s
 d
is
ea
se
; I
H
C
, i
m
m
un
oh
is
to
ch
em
is
tr
y;
 N
A
, n
ot
 a
va
ila
bl
e;
 q
PC
R
, q
ua
nt
it
at
iv
e 
po
ly
m
er
as
e 
ch
ai
n 
re
ac
ti
on
; T
N
F,
 t
um
ou
r 
ne
cr
os
is
 f
ac
to
r;
 U
C
, u
lc
er
at
iv
e 
co
lit
is
.
A
ct
iv
e 
di
se
as
e 
w
as
 d
efi
ne
d 
by
 e
nd
os
co
pi
c 
di
se
as
e 
ac
ti
vi
ty
 c
on
fir
m
ed
 b
y 
pa
th
ol
og
is
t 
ex
am
in
at
io
n 
[s
ee
 M
et
ho
ds
]. 
St
at
is
ti
ca
lly
 s
ig
ni
fic
an
t 
di
ff
er
en
ce
s 
ar
e 
no
te
d 
an
d 
fu
rt
he
r 
di
sc
us
se
d 
in
 t
he
 t
ex
t, 
*P
 <
 0
.0
5,
 *
*P
 <
 0
.0
1,
 
**
**
P
 <
 0
.0
00
1,
 u
si
ng
 t
he
 M
an
n–
W
hi
tn
ey
 t
es
t.
1194 R. Ichikawa et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/article-abstract/12/10/1191/5038446 by guest on 28 N
ovem
ber 2018
3000
2000
1000
0
αE
+c
el
ls
pe
r 
to
ta
l m
m
2
Ileum
n = 61
Colon
n = 77
Healthy Crohn’s disease
**** ****
****
***
*
*
Ulcerative colitis
Ileum
n = 17
Colon
n = 43
Ileum
n = 9
Colon
n = 72
A B
Healthy
Ileum Colon
Crohn’s
Disease
Ulcerative
Colitis
10000
5000
0
αE
+c
el
ls
pe
r 
ep
it
he
lia
l m
m
2
Ileum
n = 57
Colon
n = 76
Healthy Crohn’s disease
**** **
****
**
*
*
Ulcerative colitis
Ileum
n = 16
Colon
n = 43
Ileum
n = 8
Colon
n = 72
*
C
Figure 1. αE+ cells are more frequent in the ileum in comparison with the colon. [a] Representative images of αE staining [red] in ileal and colonic biopsies. 
Images shown are from samples with the median staining density by patient group and anatomical location. [b] All αE+ cells and [c] αE+ cells associated with 
epithelial crypts were counted in biopsies from healthy controls and patients with UC or CD. Lines and error bars show the mean ± SD. CD, Crohn’s disease; SD, 
standard deviation; UC, ulcerative colitis.
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Figure 2. ITGAE [αE] and CD3ε gene expression is higher in the ileum than colon. [a–b] αE and CD3ε gene expression were measured in ileal and colonic biopsies 
from healthy control subjects and IBD patients. Gene expression was normalized to TMEM55B. Lines and error bars show the mean ± SD. [c–d] Paired biopsies 
were taken from inflamed and uninflamed areas of the ileum and colon of IBD patients and evaluated for αE and CD3ε gene expression relative to TMEM55B. CD, 
Crohn’s disease; IBD, inflammatory bowel disease; SD, standard deviation; UC, ulcerative colitis.
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Figure 3. αE levels are correlated in paired ileal and colonic biopsies from the same subject. Paired ileal and colonic biopsies were evaluated in healthy subjects 
and IBD patients for correlation of [a] total αE+ cells or [b] epithelial-associated αE+ cells. [c] αE gene expression normalized to CD3ε expression was also 
evaluated for correlation between paired ileal and colonic biopsies. CD, Crohn’s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.
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αE high and low status by either IHC or qPCR was examined for 
concordance between the colon and ileum using a median cutoff. By 
IHC, 50% of CD patients were concordant for αE status in the colon 
and ileum, while 66% of healthy subjects and 56% of UC patients 
were similarly concordant for αE status. Using αE gene expression 
normalized to CD3ε, 74% of CD patients, 43% of healthy subjects 
and 57% of UC patients were concordant for αE status by qPCR in 
the colon and ileum.
Disease activity was assessed by both endoscopy and histology 
and correlated with biopsy αE gene expression from the same ana-
tomical region. Uninflamed biopsies were used for this analysis when 
available. No correlation was observed between αE gene expression 
and endoscopy score in UC or CD [Figure 4a–c]. There was a simi-
lar lack of correlation between αE gene expression and histological 
inflammation in UC as assessed by the Robarts Histology Index 
[RHI]27 [Figure 4d]. No difference was observed for αE+ cell density 
or αE gene expression based on inflammation or disease activity sta-
tus [Supplementary Figure 2a and b].
To evaluate αE gene expression variability over a defined segment 
of the colon, a series of biopsies were taken 2 cm apart in the sigmoid 
colon of healthy and UC subjects. Differences between intrapatient 
and interpatient variability were evaluated. First, we took the biopsy 
location with the lowest standard deviation between the patients of 
each subset [healthy SD = 0.446, UC SD = 0.589]. We then used a 
binomial test to assess if the intrapatient variability was significantly 
less than the lowest interpatient variability. We found that intrapa-
tient variability was significantly lower in healthy patients [P < 0.05] 
but not in UC patients. There were no significant differences in vari-
ability and αE gene expression levels between healthy subjects and 
UC patients [Figure 5a and b].
The effect of concomitant medication use, including corticos-
teroids and immunosuppressants, on αE+ cell density and αE gene 
expression was evaluated in both the IHC and qPCR cohorts. No 
significant differences were observed between patients based on 
current use of corticosteroids, immunosuppressants or biological 
therapy. There was a small, but significant [P  < 0.05], increase in 
CD colonic αE gene expression with 5-ASA use [Supplementary 
Figures  4–7]. No difference in αE+ cells was observed in patients 
treated with 5-ASA in the IHC cohort.
4. Discussion
The pathobiology of IBD is probably driven by complex interac-
tions between the gut microbiota and the immune system, with other 
factors such as epithelial barrier function and environmental cues 
playing key roles. Therapeutics that target inflammatory cytokines, 
such as tumour necrosis factor alpha [TNF-α] and interleukin 
[IL]-12/IL-23,28 as well as gut-selective leukocyte trafficking,29 are 
approved for IBD. Despite the widespread use of anti–TNF-α thera-
pies, fewer than half of CD30,31 and UC patients32,33 treated with these 
agents achieve remission. Furthermore, vedolizumab, which targets 
the α4β7 integrin, is less efficacious in CD than UC and among 
patients who have previously failed anti–TNF-α therapies.6,7,34,35 The 
diversity of factors driving IBD pathobiology and the significant pro-
portion of patients who fail to respond to biological therapy suggests 
that patient heterogeneity is a key driver for response to therapy in 
IBD.36 Biomarkers that enable identification of the underlying patho-
biology of disease would enable more precise treatment regimens 
and increase the likelihood of clinical benefit for individual patients. 
For a tissue-based biomarker, stable expression, irrespective of con-
comitant medications, site of biopsy and degree of inflammation, 
along with reasonable cost and ease of use, is desirable.
To better understand αE as a predictive biomarker of clinical 
remission in response to etrolizumab in IBD patients, we sought to 
further characterize αE gene expression and αE+ cell density in the 
gut in IBD patients and healthy control subjects. In this study, we 
found that both αE+ cell numbers and αE gene expression are two- to 
four-fold higher in the ileum in comparison with the colon in normal 
and IBD biopsies. Higher levels of pro-inflammatory cytokines have 
been observed in intestinal αE-expressing T cells compared with T 
cells lacking expression of αE in both healthy and UC colon.14 In our 
study, a small but significant reduction in αE+ cells was observed in 
colonic CD in comparison with healthy or UC colon; this reduction 
was not found in αE levels in the qPCR cohort. Further analysis 
showed no correlation with disease duration or number of medi-
cations [data not shown]. A  previous study using flow cytometry 
and a mixture of ileal and colonic biopsies also found a reduced 
number of αE+ cells in IBD biopsies.37 The effect on αE+ cell num-
bers and inflammatory cytokine production by these cells should be 
further investigated in CD, as cell numbers may not wholly reflect 
inflammatory potential. Correlation between αE+ cells was observed 
between matched ileal and colonic biopsies. αE gene expression 
normalized to CD3ε, a marker gene for T cells, was also correlated 
between these two anatomical regions. Across our cohorts, approxi-
mately two-thirds of patients were concordant [αE high/αE high or 
αE low/αE low] for αE status in the colon and in the ileum when a 
median cutoff was used for patient categorization.4 Differences in 
αE levels were not impacted by inflammation status of the biopsy or 
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Figure 5. Intrapatient variability of αE gene expression levels is lower than interpatient variability. [a] Serial colonic biopsies were taken from healthy subjects 
and UC patients and evaluated for αE gene expression. [b] αE gene expression variability by disease indication. All gene expression levels are normalized to 
TMEM55B. Lines and error bars show the mean ± SD. IBD, inflammatory bowel disease; SD, standard deviation; UC, ulcerative colitis.
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concomitant medications, except for a small effect of 5-ASA that is 
not currently understood. Greater variability was observed between 
patients than within patients when αE gene expression was assessed 
across multiple biopsies from the sigmoid colon, suggesting that αE 
could serve as a biomarker to stratify patients, with low intrapatient 
sampling variability. Caveats to this study include the retrospective 
nature of the analysis and the small sample size, particularly for the 
intrapatient variability analysis.
As dictated by the clinical standard of care, IBD patients routinely 
undergo endoscopy and/or flexible sigmoidoscopy with concurrent 
mucosal biopsies to document the severity of histological disease 
activity and to screen for dysplasia. Despite the ready availability 
of mucosal biopsies from patients with IBD, biopsy-based predictive 
biomarker approaches to identifying patients likely to respond to 
targeted therapies have not yet been used for IBD. The identification 
and validation of such a predictive biomarker requires careful char-
acterization of many possible sources of variability of biomarker 
expression including inflammation status and the intrinsic anatom-
ical variability in biomarker levels, either within or between intes-
tinal segments.
The effect of inflammation on αE expression was not tested in 
the etrolizumab phase 2 UC study, as all patients enrolled in the 
study had evidence of active endoscopic disease [endoscopic sub-
score ≥ 2], and biopsies were taken from an inflamed region in a 
standardized area of the sigmoid colon without paired sampling 
of uninflamed mucosa. A significant decrease in the proportion of 
crypt-associated αE+ cells and αE gene expression was observed fol-
lowing etrolizumab treatment.4 In our study, we observed no effect 
of inflammation status on αE levels, either through paired biopsies 
taken in areas judged by the endoscopist to be inflamed and unin-
flamed, or by correlation with endoscopy or histology score.
The differences in αE levels between different anatomical regions 
may provide an additional challenge when areas of active inflamma-
tion are irregularly distributed throughout the intestine, such as in 
CD. Here, inflamed regions, in particular the ileum, may be beyond 
the reach of the endoscope because of technical challenges includ-
ing inflammatory or fibrotic stricturing. Previous work has described 
increased αE levels in the proximal colon in comparison with the 
distal colon.17,19,20 We found that αE expression was increased in 
the ileum in comparison with the sigmoid colon. Furthermore, αE 
expression in the colon and ileum were moderately correlated; this 
finding could be useful in patients in whom biopsy of the ileum is 
not possible. For this study, we used median cutoffs based on the 
sample population to designate high or low αE status; further work 
will be required to prospectively evaluate cutoffs for their potential 
predictive value.
Variability of gene expression or αE+ cell numbers within an ana-
tomical intestinal segment may also affect the interpretation of a 
biopsy-based diagnostic. Previous work on inflammatory biomark-
ers has shown that 1–6 biopsies may be required to reduce sampling 
error to less than 25%.38 Because αE expression does not appear to 
be influenced by inflammation, its variability would be expected to 
be less than that of an inflammatory gene such as TNF-α. We evalu-
ated a small cohort of UC patients and healthy controls to deter-
mine whether interpatient variability was greater than intrapatient 
variability for αE gene expression and found less variability within 
a given patient than between patients. This finding indicates that 
sampling error differences may be small enough to support a biopsy-
based biomarker test. Because αE expression does not appear to be 
influenced by inflammation, its variability would be expected to be 
less than that of an inflammatory gene such as TNF-α or IP-10.38 
The stability of αE expression makes it favourable for biomarker 
development.
A key role for α4β1-mediated trafficking to the ileum was 
observed in an adoptive transfer model using effector T cells from 
CD patients,39 suggesting that the blockade of α4β7 alone may not 
be sufficient to induce remission in all CD patients. UC patients with 
higher αE expression in baseline endoscopic mucosal biopsies as 
determined by qPCR or IHC had an enrichment of remission follow-
ing etrolizumab treatment in an exploratory post hoc analysis of the 
phase 2 clinical study.4,15 These data suggest that the pathobiology 
of disease in patients with increased αE expression in gut tissue may 
be preferentially targeted by etrolizumab treatment.15 In this study, 
we confirm17,18 and extend the finding of a higher prevalence of αE+ 
cells in the ileum and proximal colon, a site of inflammation for a 
substantial proportion of CD patients. The additional blockade of 
αEβ7-mediated interactions may provide an additional mechanism 
of action in CD.
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